# Quan Sing Ng

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/quan-sing-ng/

## Facts

| Field | Value |
| --- | --- |
| Citations | 2,909 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 28 |
| i10-index | 52 |
| Last Known Institution | National Cancer Centre Singapore |
| OpenAlex ID | https://openalex.org/A5043046640 |
| ORCID iD | 0000-0002-5815-6900 |
| Works | 159 |

## Researcher papers

- [Non–Small Cell Lung Cancer: Histopathologic Correlates for Texture Parameters at CT](https://scholariq.org/papers/non-small-cell-lung-cancer-histopathologic-correlates-for-texture-parameters-at/)
- [Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/addition-of-radium-223-to-abiraterone-acetate-and-prednisone-or-prednisolone-in/)
- [Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis](https://scholariq.org/papers/utility-of-incorporating-next-generation-sequencing-ngs-in-an-asian-non-small/)
- [Clonal <i>MET</i> Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer](https://scholariq.org/papers/clonal-i-met-i-amplification-as-a-determinant-of-tyrosine-kinase-inhibitor/)
- [Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial](https://scholariq.org/papers/pembrolizumab-monotherapy-versus-chemotherapy-in-platinum-pretreated-recurrent/)
- [Pembrolizumab-induced Stevens–Johnson syndrome in non-melanoma patients](https://scholariq.org/papers/pembrolizumab-induced-stevens-johnson-syndrome-in-non-melanoma-patients/)
- [Pan-Asian adaptation of the EHNS–ESMO–ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck](https://scholariq.org/papers/pan-asian-adaptation-of-the-ehns-esmo-estro-clinical-practice-guidelines-for-the/)
- [EGFR Mutation Subtypes Influence Survival Outcomes following First-Line Gefitinib Therapy in Advanced Asian NSCLC Patients](https://scholariq.org/papers/egfr-mutation-subtypes-influence-survival-outcomes-following-first-line/)
- [Quantitative Assessment of Lung Cancer Perfusion Using MDCT: Does Measurement Reproducibility Improve with Greater Tumor Volume Coverage?](https://scholariq.org/papers/quantitative-assessment-of-lung-cancer-perfusion-using-mdct-does-measurement/)
- [A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC)](https://scholariq.org/papers/a-phase-ib-study-of-selumetinib-azd6244-arry-142886-in-combination-with/)
- [EP12.01-31 Updated First-line Osimertinib in Asian patients with Advanced EGFR-mutated Lung Cancer](https://scholariq.org/papers/ep12-01-31-updated-first-line-osimertinib-in-asian-patients-with-advanced-egfr/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)

## Researcher university

- [National Cancer Centre Singapore](https://scholariq.org/institutions/national-cancer-centre-singapore/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.